intrahepat
cholangiocarcinoma
tissu
specimen
obtain
patient
underw
hepatectomi
kyoto
univers
hospit
written
inform
consent
tumor
histolog
diagnos
cholangiocarcinoma
pathologist
profil
gene
express
cdna
microarray
analysi
carri
describ
transgen
mice
describ
previous
kindli
provid
dr
fa
lemonni
depart
unit
immunit
cellulair
antiviral
institut
pasteur
franc
peptid
puriti
purchas
anygen
gwangju
south
korea
three
human
cholangiocarcinoma
tfk
mec
two
human
hepatocellular
carcinoma
human
lung
cancer
cell
line
includ
adenocarcinoma
two
carcinoma
squamou
cell
carcinoma
adenosquam
carcinoma
carcinoma
lung
cancer
use
human
saec
cell
use
control
transport
associ
antigen
process
tap
cell
line
colon
cancer
cell
line
obtain
riken
bioresourc
center
tsukuba
japan
cell
maintain
vitro
rpmi
medium
dmem
supplement
heat
inactiv
fetal
calf
serum
except
cell
cultur
medium
supplement
heat
inactiv
fetal
calf
serum
saec
cell
grown
optim
medium
sagm
purchas
cambrex
bio
scienc
walkersvil
md
clinic
research
use
pbmc
donor
approv
institut
review
board
kumamoto
univers
blood
sampl
obtain
healthi
donor
patient
either
cholangiocarcinoma
lung
cancer
provid
written
inform
consent
express
examin
flowcytometri
monoclon
antibodi
one
lambda
canoga
park
ca
select
donor
cancer
tissu
excis
patient
surgeri
obtain
written
inform
consent
total
rna
extract
cell
line
tissu
use
rneasi
kit
qiagen
dusseldorf
germani
accord
manufactur
instruct
total
rna
human
normal
tissu
purchas
clontech
palo
alto
ca
done
describ
primer
sequenc
detect
three
splice
variant
detect
variant
gapdh
actb
northern
blot
analysi
done
describ
gel
total
rna
human
normal
tissu
clontech
per
lane
blot
onto
nylon
membran
membran
hybrid
cdna
probe
blot
autoradiograph
intensifi
screen
hr
immunohistochem
analysi
done
describ
section
cholangiocarcinoma
lung
cancer
specimen
stain
mous
monoclon
antibodi
clone
abnova
taipei
taiwan
standard
procedur
stain
signal
visual
use
dakocytom
envis
dakocytom
carpinteria
ca
cdna
encod
tag
influenza
viru
hemagglutinin
ha
clone
pentr
vector
invitrogen
carlsbad
ca
transfer
lentiviru
express
vector
lr
recombin
reaction
invitrogen
gene
transfer
perform
describ
express
protein
confirm
western
blot
analysi
use
horseradish
peroxidas
hrp
rat
monoclon
antibodi
clone
roch
mannheim
germani
also
detect
use
mous
monoclon
antibodi
clone
sigma
st
loui
mo
rabbit
igg
amersham
bioscienc
piscataway
nj
antibodi
signal
develop
visual
use
chemiluminesc
system
ecl
amersham
bioscienc
immun
mice
bone
dc
done
previous
spleen
cell
isol
immun
mice
frequenc
cell
produc
among
cell
upon
stimul
syngen
puls
without
peptid
assay
immunospot
elispot
assay
previous
cell
overnight
cultur
presenc
peptid
sigma
st
loui
mo
medium
hr
subsequ
hr
level
express
cell
surfac
analyz
flow
cytometri
use
monoclon
antibodi
human
peptid
qydpvaalf
neg
control
peptid
nlneslidl
sar
ctl
epitop
peptid
high
bind
affin
work
prepar
posit
control
also
use
fluoresc
index
fi
calcul
mean
fluoresc
intens
mfi
express
cell
determin
flow
cytometri
use
formula
fi
mfi
cell
peptid
mfi
cell
pbmc
isol
heparin
blood
japanes
cancer
patient
healthi
donor
densiti
gradient
centrifug
peripher
dendrit
cell
dc
gener
previous
cell
isol
use
microbead
miltenyl
biotec
bergisch
gladbach
germani
pbmc
donor
thereaft
ctl
gener
six
day
last
stimul
respons
ctl
analyz
elispot
assay
describ
also
releas
assay
describ
briefli
label
target
cell
suspend
assay
medium
seed
well
plate
variou
number
effector
cell
suspend
assay
medium
ad
well
incub
hr
supernat
collect
well
measur
radioact
statist
signific
differenti
find
among
experiment
group
determin
student
avalu
p
consid
statist
signific
laser
cdna
microarray
analysi
case
intrahepat
cholangiocarcinoma
report
data
use
search
gene
show
high
rel
express
ratio
cancer
cell
normal
epitheli
cell
intrahepat
bile
duct
process
identifi
gene
greater
increas
express
cancer
cell
tissu
sampl
fig
among
gene
express
exhibit
greatest
increas
express
cancer
cell
comparison
normal
cell
fig
therefor
evalu
candid
antigen
immunotherapi
express
analyz
kind
normal
tissu
includ
fetal
kidney
liver
also
cell
lung
cancer
esophag
cancer
use
cdna
microarray
fig
b
express
testi
bone
marrow
small
intestin
thymu
fetal
liver
among
normal
tissu
howev
level
express
normal
tissu
far
lower
cell
lung
carcinoma
esophag
cancer
tissu
fig
b
previous
report
data
cdna
microarray
analysi
variou
kind
cancer
use
analyz
express
differ
type
cancer
tissu
support
inform
tabl
show
express
elev
variou
cancer
tissu
particularli
enhanc
express
recogn
bladder
cancer
lung
cancer
small
cell
carcinoma
cell
carcinoma
pancreat
cancer
investig
conduct
cholangiocarcinoma
also
lung
cancer
lung
cancer
common
caus
cancer
death
western
express
gene
cholangiocarcinoma
hepatocellular
carcinoma
lung
cancer
cell
line
adenocarcinoma
carcinoma
squamou
cell
carcinoma
adenosquam
carcinoma
larg
cell
carcinoma
small
cell
carcinoma
lung
cancer
tissu
analyz
gene
contain
exon
altern
express
give
rise
differenti
express
mrna
cholangiocarcinoma
cell
line
tfk
mec
hepatocellular
carcinoma
cell
line
strongli
express
mrna
fig
express
lung
cancer
cell
line
examin
support
inform
fig
addit
tissu
sampl
lung
adenocarcinoma
squamou
cell
carcinoma
small
cell
carcinoma
also
express
mrna
wherea
normal
lung
epithelium
support
inform
fig
strongli
express
cancer
cell
line
examin
except
colon
cancer
cell
line
express
trace
amount
mrna
data
shown
among
normal
tissu
specimen
mrna
express
testi
fetal
liver
thymu
stomach
small
intestin
colon
fig
northern
blot
analysi
reveal
rel
strong
express
mrna
testi
weak
express
fetal
liver
thymu
gastrointestin
tract
fig
northern
blot
analys
consist
result
cdna
microarray
analysi
fig
b
tissu
sampl
cholangiocarcinoma
lung
cancer
analyz
immunohistochem
determin
express
protein
cancer
cell
fig
increas
express
protein
observ
cancer
tissu
adjac
normal
tissu
human
peptid
carri
bind
motif
search
use
bima
softwar
packag
bioinformat
molecular
analysi
section
center
inform
technolog
nih
bethesda
md
http
wwwbimascitnihgov
syfpeithi
biomed
informat
http
wwwsyfpeithid
select
peptid
predict
bind
amino
acid
sequenc
conserv
among
human
isoform
score
select
peptid
calcul
base
bima
syfpeithi
algorithm
predict
affin
shown
tabl
investig
conduct
identifi
epitop
select
peptid
use
tgm
peptid
load
onto
tgm
inject
intraperiton
twice
mice
interv
spleen
cell
isol
mice
day
second
inject
cultur
puls
peptid
subsequ
cultur
cell
subject
elispot
assay
analyz
product
upon
stimul
peptid
seri
repeat
experi
reveal
reproduc
respons
design
respect
tabl
fig
hand
ctl
line
respond
peptid
puls
onto
thu
verifi
respons
peptid
restrict
amino
acid
sequenc
conserv
human
mous
wherea
conserv
human
glmdlsttpl
vs
mous
glm
elnttpl
determin
whether
immun
mice
peptid
caus
autoimmun
histolog
analysi
done
variou
organ
isol
tgm
immun
peptid
observ
patholog
chang
lymphocyt
infiltr
tissu
destruct
repair
brain
heart
lung
liver
small
intestin
kidney
testi
immun
tgm
data
shown
result
suggest
ctl
respons
elicit
immun
peptid
may
caus
damag
normal
tissu
know
whether
identifi
peptid
actual
bind
analyz
bind
peptid
use
cell
shown
figur
stabil
cell
surfac
addit
peptid
observ
thu
confirm
actual
bind
peptid
thereaft
investig
human
ctl
respons
tri
establish
ctl
line
pbmc
healthi
individu
stimul
peptid
cell
sort
pbmc
autolog
dc
puls
peptid
describ
materi
method
ctl
line
gener
posit
healthi
donor
produc
specif
respons
cell
puls
peptid
fig
investig
examin
whether
identifi
peptid
produc
protein
intracellular
natur
process
kill
activ
ctl
induc
peptid
cancer
patient
analyz
releas
assay
analys
reveal
posit
cell
line
examin
express
fig
support
inform
fig
data
shown
except
cell
thu
introduc
cell
express
vector
use
lentiviru
use
target
cell
cell
infect
lentivirus
without
also
use
neg
control
target
cell
express
protein
transfect
confirm
shown
figur
ctl
line
exhibit
significantli
higher
cytotox
cell
cell
result
clearli
indic
peptid
natur
process
protein
present
context
recogn
ctl
identif
adequ
target
antigen
induc
potent
specif
immun
respons
import
develop
cancer
immunotherapi
although
mani
taa
variou
cancer
antigen
specif
express
cholangiocarcinoma
previou
cdna
microarray
analysi
identifi
multipl
gene
transcript
current
studi
search
taa
use
cdna
microarray
data
identifi
candid
target
antigen
number
aggress
human
enhanc
express
also
observ
variou
cancer
tissu
cdna
microarray
analysi
support
inform
tabl
express
significantli
associ
poor
overal
surviv
cell
lung
cancer
glioblastoma
therefor
may
potenti
serv
good
target
cancer
immunotherapi
variou
type
cancer
evalu
target
cancer
immunotherapi
present
studi
examin
immunogen
human
immun
system
peptid
predict
bind
analyz
capac
induc
ctl
stimul
pbmc
obtain
healthi
donor
ylvpiqfpv
slvlqpsvkv
glmdlsttpl
peptid
result
gener
ctl
line
furthermor
ctl
reactiv
peptid
gener
cancer
patient
exhibit
specif
cytotox
cell
introduc
express
vector
cell
thu
verifi
natur
process
peptid
protein
cancer
cell
result
suggest
promis
target
variou
type
cancer
peptid
deriv
effect
tool
clinic
applic
immunotherapi
cancer
patient
human
gene
structur
two
exon
va
viia
altern
differenti
splice
exon
va
viia
human
yield
isoform
contain
altern
exon
contain
none
altern
exon
retain
exon
exhibit
transactiv
activ
absenc
viia
inhibitori
sequenc
presenc
viia
render
transcript
present
studi
found
express
variou
cancer
cell
sampl
differenti
pattern
express
normal
testi
thymu
isoform
abund
cultur
cell
includ
normal
gastrointestin
tract
result
consist
find
transcript
factor
play
import
role
regul
express
gene
involv
cell
growth
prolifer
differenti
longev
transform
express
profil
identifi
cluster
gene
includ
mani
gene
cyclin
b
etc
loss
express
cancer
cell
line
result
mitot
spindl
defect
delay
cell
mitosi
induc
mitot
find
suggest
express
essenti
cancer
cell
growth
surviv
inde
evid
express
mrna
detect
cell
line
examin
present
studi
molecul
express
cancer
cell
play
essenti
role
surviv
cancer
cell
escap
immun
cell
attack
direct
molecul
lose
express
regard
thu
consid
suitabl
target
immunotherapi
hla
tgm
use
identif
antigen
epitop
also
evalu
autoimmun
caus
immun
peptid
conserv
human
mous
amino
acid
sequenc
peptid
conserv
human
mous
present
studi
vaccin
peptid
induc
autoimmun
tgm
result
suggest
use
peptid
human
would
safe
although
low
level
express
detect
normal
organ
fig
number
clinic
trial
evalu
peptid
deriv
taa
howev
tumor
regress
far
observ
possibl
reason
lack
clinic
efficaci
could
entri
advanc
cancer
patient
immunotherapi
trial
loss
hla
class
molecul
molecul
protein
associ
antigen
present
tap
protein
lmp
tumor
consequ
signific
portion
tumor
cell
could
escap
ctl
specif
peptid
present
hla
class
molecul
even
ctl
could
success
induc
taa
peptid
vaccin
capabl
target
tumor
cell
present
studi
investig
express
tumor
gene
specimen
intrahepat
cholangiocarcinoma
tissu
use
cdna
microarray
analysi
gene
associ
immun
escap
observ
data
shown
result
suggest
immunotherapi
cholangiocarcinoma
could
effect
recent
two
inhibitor
transcript
activ
identifi
target
inhibitor
effect
anticanc
therapi
one
peptid
contain
amino
acid
sequenc
interact
transactiv
domain
inhibit
transcript
activ
peptid
caus
select
apoptosi
hepatocellular
carcinoma
reduc
prolifer
angiogenesi
hepatocellular
carcinoma
region
adjac
normal
liver
tissu
antibiot
thiazol
compound
siomycin
antibiot
inhibit
growth
select
induc
apoptosi
could
potenti
anticanc
drug
although
result
base
experi
cell
line
transgen
mice
clinic
trial
vaccin
deriv
taa
identifi
cdna
microarray
analys
differ
cancer
current
underway
epitop
identifi
present
studi
may
well
clinic
test
near
futur
